1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Stepping Up? Pharma’s Early COVID Pricing Decisions May Be Resolving Concerns

 
• By Cathy Kelly

Cigna's Steve Miller suggests pharma is taking a responsible approach to pricing during the pandemic in a policy discussion convened by the Institute for Clinical and Economic Review on pricing models for COVID-19 drugs and vaccines.

SCRANTON, PA - MAY 24:Indianapolis Indians second baseman Josh Harrison steps up to the plate in a game against the Scranton Wilkes Barre Yankees at PNC Field on May 24, 2011 in Scranton, PA.
At The Plate on COVID-19 • Source: Shutterstock

Pharmaceutical manufacturers so far appear to be making good on pledges to ensure that COVID-19 drugs and vaccines will be priced in a way that ensures access and affordability during the pandemic, according to a leading US payer participating in a series of recent colloquiums convened by the Institute for Clinical and Economic Review.

The discussions were part of an ICER initiative to develop a consensus on appropriate pricing for COVID-19 drugs and vaccines....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe

 
• By Francesca Bruce

European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By Cathy Kelly

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 
• By Francesca Bruce

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.

More from Market Access

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

Saving Part D: US Medicare Advisors Sound The Alarm

 
• By Michael McCaughan

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe

 
• By Francesca Bruce

The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.